Aprea Therapeutics Inc (APRE)

Jan 09, 2026

Aprea Therapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets

Jan 09, 2026

Jan 09, 2026

Why Aprea Therapeutics Inc. stock is a value investor pickEarnings Risk Report & Weekly Hot Stock Watchlists - ulpravda.ru

Jan 09, 2026

Jan 08, 2026

Why retail investors favor Aprea Therapeutics Inc. stockMarket Weekly Review & Weekly Chart Analysis and Guides - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Why Aprea Therapeutics Inc. stock is considered a top pickJuly 2025 Analyst Calls & Weekly High Conviction Ideas - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Will Aprea Therapeutics Inc. stock outperform growth indexesInsider Selling & Weekly Setup with High ROI Potential - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Can Aprea Therapeutics Inc. stock reach $100 price targetM&A Rumor & High Accuracy Trade Signal Alerts - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Will Aprea Therapeutics Inc. stock reach all time highs in 2025Sell Signal & Technical Confirmation Alerts - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Will Aprea Therapeutics Inc. stock deliver consistent dividendsJuly 2025 Rallies & Low Risk Growth Stock Ideas - ulpravda.ru

Jan 08, 2026

Jan 08, 2026

Why retail investors pile into Aprea Therapeutics Inc. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - ulpravda.ru

Jan 08, 2026

Jan 07, 2026

MSN Money - MSN

Jan 07, 2026

Jan 07, 2026

Aprea Therapeutics files to sell 5.5M shares of common stock for holders - MSN

Jan 07, 2026

Jan 06, 2026

Aprea signals 2026 inflection as cancer trials advance and cash extends - MSN

Jan 06, 2026

Jan 02, 2026

Market Recap: Will Aprea Therapeutics Inc stock reach all time highs in 2025 - moha.gov.vn

Jan 02, 2026

Dec 29, 2025

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Down 41.3% in December - Defense World

Dec 29, 2025

Dec 29, 2025

Aprea Therapeutics (NASDAQ:APRE) vs. Affymax (OTCMKTS:AFFY) Financial Survey - Defense World

Dec 29, 2025

Dec 28, 2025

Halda Therapeutics Appoints Veteran Biopharma Leader, Christian Schade, as President and Chief Executive Officer - Quantisnow

Dec 28, 2025

Dec 24, 2025

Maxim Group Reaffirms Their Buy Rating on Aprea Therapeutics (APRE) - The Globe and Mail

Dec 24, 2025

Dec 24, 2025

Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends - MyChesCo

Dec 24, 2025

Dec 23, 2025

Can Aprea Therapeutics Inc. stock weather global recessionEnergy Sector Updates & Small Budget Capital Investment - bollywoodhelpline.com

Dec 23, 2025

Dec 22, 2025

Aprea Therapeutics (APRE) Stock Analysis Report | Financials & Insights - Benzinga

Dec 22, 2025

Dec 20, 2025

Will Aprea Therapeutics Inc. stock benefit from automationTrade Performance Summary & Weekly Return Optimization Alerts - Улправда

Dec 20, 2025

Dec 20, 2025

Why Aprea Therapeutics Inc. stock could rally in 20252025 Big Picture & Low Drawdown Investment Ideas - Улправда

Dec 20, 2025

Dec 19, 2025

Aprea Therapeutics (NASDAQ:APRE) Given New $5.00 Price Target at HC Wainwright - Defense World

Dec 19, 2025

Dec 19, 2025

Aprea Therapeutics reports progress in cancer drug development By Investing.com - Investing.com South Africa

Dec 19, 2025

Dec 18, 2025

HC Wainwright & Co. Maintains Aprea Therapeutics (APRE) Buy Recommendation - Nasdaq

Dec 18, 2025

Dec 18, 2025

APRE Analyst Forecasts - Quiver Quantitative

Dec 18, 2025

Dec 18, 2025

Aprea Therapeutics (APRE): HC Wainwright Maintains 'Buy' Rating, Lowers Price Target | APRE Stock News - GuruFocus

Dec 18, 2025

Dec 18, 2025

Aprea Therapeutics CEO issues letter to shareholders highlighting outlook for 2026 - marketscreener.com

Dec 18, 2025

Dec 18, 2025

Aprea Therapeutics reports progress in cancer drug development - Investing.com

Dec 18, 2025

Dec 18, 2025

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026 - The Manila Times

Dec 18, 2025

Dec 18, 2025

Aprea Therapeutics Highlights Clinical Progress and Strategic Plans in Shareholder Update Letter - Quiver Quantitative

Dec 18, 2025

Dec 17, 2025

Aprea Therapeutics Earnings Notes - Trefis

Dec 17, 2025

Dec 12, 2025

Aprea Therapeutics Advances ATRN-119 Study for Solid Tumors - MSN

Dec 12, 2025

Dec 11, 2025

Insider Buying: John Hamill Acquires Additional Shares of Aprea Therapeutics Inc (APRE) - GuruFocus

Dec 11, 2025

Dec 11, 2025

Hamill, Aprea Therapeutics CFO, buys $5,825 in stock By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Aprea therapeutics director Duey Marc buys $25,000 in shares By Investing.com - Investing.com Canada

Dec 11, 2025

Dec 11, 2025

Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock - Investing.com India

Dec 11, 2025

Dec 11, 2025

Hamill, Sr. VP at Aprea Therapeutics, buys $5,825 in stock By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Hamill, Aprea Therapeutics CFO, buys $5,825 in stock - Investing.com

Dec 11, 2025

Dec 11, 2025

Aprea Therapeutics Director Marc Duey Acquires 21,459 Shares - TradingView — Track All Markets

Dec 11, 2025

Dec 11, 2025

Dir Duey Buys 21,459 ($25K) Of Aprea Therapeutics Inc [APRE] - TradingView — Track All Markets

Dec 11, 2025

Dec 09, 2025

Aprea Therapeutics raises $3.1 million in private placement By Investing.com - Investing.com Canada

Dec 09, 2025

Dec 09, 2025

Aprea Therapeutics, Inc. announced that it expects to receive $3.055822 million in funding - marketscreener.com

Dec 09, 2025

Dec 09, 2025

Aprea Therapeutics raises $3.1 million in private placement - Investing.com

Dec 09, 2025

Dec 09, 2025

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times

Dec 09, 2025

Dec 09, 2025

Aprea Therapeutics (Nasdaq: APRE) prices $3.1M private placement to extend cash runway into Q1 2027 - Stock Titan

Dec 09, 2025

Dec 08, 2025

Aprea Therapeutics (NASDAQ: APRE) registers 219,242 shares under 2019 equity plan - Stock Titan

Dec 08, 2025